TY - JOUR
T1 - Variation in Proton Craniospinal Irradiation Practice Patterns in the United States
T2 - A Pediatric Proton Consortium Registry (PPCR) Study
AU - Connor, Michael
AU - Paulino, Arnold C.
AU - Ermoian, Ralph P.
AU - Hartsell, William F.
AU - Indelicato, Daniel J.
AU - Perkins, Stephanie
AU - Mangona, Victor
AU - DeNunzio, Nicholas
AU - Laack, Nadia N.
AU - Hill-Kayser, Christine
AU - Kwok, Young
AU - Chang, John Han Chih
AU - Yock, Torunn
AU - MacEwan, Iain
N1 - Funding Information:
M.C. received funding from ACRO resident seed grant 2021; PPCR: federal share of program income earned by Massachusetts General Hospital on C06 CA059267, Proton Therapy Research and Treatment Center.
Funding Information:
Disclosures: J.H.-C.: none. M.C. received support for the present manuscript, attending meetings, and/or travel from ACRO resident grant. N.D.: none. R.P.E.: none. W.F.H.: none. C.H.-K.: none. D.J.I. received a grant from the National Cancer Institute within the past 36 months for participation on the NCI Pediatric CIRB. Y.K.: none. N.N.L: none. I.M.: none. A.D.C.P.: none. S.P. is a paid member of a medical advisory committee, Mevion Medical Systems. T.Y. received financial support from MIM, IBA, Protom, MGH Funds, and MGH/NCI federal share grant funds, and IBA sponsored educational symposium talk on proton therapy for medulloblastoma; chair of the PCG (Proton Collaborative Group) Data Safety Monitoring Board; and advisory board member, Ronald MacDonald House Charity at Boston Harbour.
Funding Information:
M.C. received funding from ACRO resident seed grant 2021; PPCR: federal share of program income earned by Massachusetts General Hospital on C06 CA059267, Proton Therapy Research and Treatment Center. Disclosures: J.H.-C.: none. M.C. received support for the present manuscript, attending meetings, and/or travel from ACRO resident grant. N.D.: none. R.P.E.: none. W.F.H.: none. C.H.-K.: none. D.J.I. received a grant from the National Cancer Institute within the past 36 months for participation on the NCI Pediatric CIRB. Y.K.: none. N.N.L: none. I.M.: none. A.D.C.P.: none. S.P. is a paid member of a medical advisory committee, Mevion Medical Systems. T.Y. received financial support from MIM, IBA, Protom, MGH Funds, and MGH/NCI federal share grant funds, and IBA sponsored educational symposium talk on proton therapy for medulloblastoma; chair of the PCG (Proton Collaborative Group) Data Safety Monitoring Board; and advisory board member, Ronald MacDonald House Charity at Boston Harbour.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/3/15
Y1 - 2022/3/15
N2 - Purpose: Craniospinal irradiation (CSI) is commonly used for pediatric brain tumors with a propensity for spread in craniospinal fluid, principally medulloblastoma. Evolving technology has led to the use of highly conformal radiation therapy (RT) techniques for CSI, including proton therapy. Target delineation and plan coverage are critical for CSI, but there is ongoing controversy and variability in these realms, with little available data on practice patterns. We sought to characterize proton CSI practice patterns in the United States by examining CSI plans in the Pediatric Proton/Photon Consortium Registry (PPCR). Materials and Methods: PPCR was queried for data on proton CSI patients from 2015 to early 2020. Each plan was manually reviewed, determining patient position; prescription dose; and coverage of optic nerves, vertebral bodies, spinal nerve roots, sacral nerves, and cranial foramina, among other variables. Two radiation oncologists blinded to clinical data and treating institution assessed coverage at the 95% prescription isodose line and per published European Society for Paediatric Oncology guidelines. Variability in coverage was assessed with nonparametric tests and univariate and multivariate logistic regression. Results: PPCR supplied data for 450 patients, 384 of whom had an evaluable portion of a CSI plan. Most patients (90.3%) were supine. Optic nerves were fully covered in 48.2%; sacral nerves in 87.7%; cranial foramina in 69.3%; and spinal nerves in 95.6%. Vertebral body (VB) sparing was used in 18.6% of skeletally immature cases, increasing over time (P < .001). Coverage in all categories was significantly different among treating institutions, on univariate and multivariate analyses. Cribriform plate deficits were rare, with marginal misses of the foramen ovale (17.4%) and frontal lobe (12%) most common. Conclusion: We found consistent variation based on treating institution in proton CSI practices including optic nerve, VB, sacral nerve, cranial, and spinal nerve coverage. These data may serve as a baseline quantification of current proton CSI practices in the United States as they continue to evolve.
AB - Purpose: Craniospinal irradiation (CSI) is commonly used for pediatric brain tumors with a propensity for spread in craniospinal fluid, principally medulloblastoma. Evolving technology has led to the use of highly conformal radiation therapy (RT) techniques for CSI, including proton therapy. Target delineation and plan coverage are critical for CSI, but there is ongoing controversy and variability in these realms, with little available data on practice patterns. We sought to characterize proton CSI practice patterns in the United States by examining CSI plans in the Pediatric Proton/Photon Consortium Registry (PPCR). Materials and Methods: PPCR was queried for data on proton CSI patients from 2015 to early 2020. Each plan was manually reviewed, determining patient position; prescription dose; and coverage of optic nerves, vertebral bodies, spinal nerve roots, sacral nerves, and cranial foramina, among other variables. Two radiation oncologists blinded to clinical data and treating institution assessed coverage at the 95% prescription isodose line and per published European Society for Paediatric Oncology guidelines. Variability in coverage was assessed with nonparametric tests and univariate and multivariate logistic regression. Results: PPCR supplied data for 450 patients, 384 of whom had an evaluable portion of a CSI plan. Most patients (90.3%) were supine. Optic nerves were fully covered in 48.2%; sacral nerves in 87.7%; cranial foramina in 69.3%; and spinal nerves in 95.6%. Vertebral body (VB) sparing was used in 18.6% of skeletally immature cases, increasing over time (P < .001). Coverage in all categories was significantly different among treating institutions, on univariate and multivariate analyses. Cribriform plate deficits were rare, with marginal misses of the foramen ovale (17.4%) and frontal lobe (12%) most common. Conclusion: We found consistent variation based on treating institution in proton CSI practices including optic nerve, VB, sacral nerve, cranial, and spinal nerve coverage. These data may serve as a baseline quantification of current proton CSI practices in the United States as they continue to evolve.
UR - http://www.scopus.com/inward/record.url?scp=85121918552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121918552&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2021.11.016
DO - 10.1016/j.ijrobp.2021.11.016
M3 - Article
C2 - 34808253
AN - SCOPUS:85121918552
SN - 0360-3016
VL - 112
SP - 901
EP - 912
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 4
ER -